Novel antibiotics: Are we still in the pre-post-antibiotic era?

作者：Draenert R^*; Seybold U; Gruetzner E; Bogner J R

来源：Infection, 2015, 43(2): 145-151.

DOI：10.1007/s15010-015-0749-y

• Tedizolid
• Ceftolozane
• Omadacycline
• Avibactam
• Cadazolid

Therapeutic efficacy and safety in infections due to multidrug-resistant bacteria can be improved by the clinical development of new compounds and devising new derivatives of already useful antibiotics. Due to a striking global increase in multidrug-resistant Gram-positive but even more Gram-negative organisms, new antibiotics are urgently needed.
This paper provides a review of novel antibiotic compounds which are already in clinical development, mainly in phase III clinical trials.
Each of these new trials increases the possibility of new antibiotics receiving approval.

• 出版日期2015-4